Literature DB >> 22897946

N-Benzoyl anthranilic acid derivatives as selective inhibitors of aldo-keto reductase AKR1C3.

Maša Sinreih1, Izidor Sosič, Nataša Beranič, Samo Turk, Adegoke O Adeniji, Trevor M Penning, Tea Lanišnik Rižner, Stanislav Gobec.   

Abstract

Human aldo-keto reductases AKR1C1-AKR1C3 are involved in the biosynthesis and inactivation of steroid hormones and prostaglandins and thus represent attractive targets for the development of new drugs. We synthesized a series of N-benzoyl anthranilic acid derivatives and tested their inhibitory activity on AKR1C enzymes. Our data show that these derivatives inhibit AKR1C1-AKR1C3 isoforms with low micromolar potency. In addition, five selective inhibitors of AKR1C3 were identified. The most promising inhibitors were compounds 10 and 13, with IC(50) values of 0.31 μM and 0.35 μM for AKR1C3, respectively.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22897946      PMCID: PMC4038446          DOI: 10.1016/j.bmcl.2012.07.062

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  20 in total

1.  Crystal structures of AKR1C3 containing an N-(aryl)amino-benzoate inhibitor and a bifunctional AKR1C3 inhibitor and androgen receptor antagonist. Therapeutic leads for castrate resistant prostate cancer.

Authors:  Mo Chen; Adegoke O Adeniji; Barry M Twenter; Jeffrey D Winkler; David W Christianson; Trevor M Penning
Journal:  Bioorg Med Chem Lett       Date:  2012-03-29       Impact factor: 2.823

Review 2.  Inhibitors of aldo-keto reductases AKR1C1-AKR1C4.

Authors:  P Brožič; S Turk; T Lanišnik Rižner; S Gobec
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

3.  Aldo-keto reductases AKR1C1, AKR1C2 and AKR1C3 may enhance progesterone metabolism in ovarian endometriosis.

Authors:  N Hevir; K Vouk; J Sinkovec; M Ribič-Pucelj; T Lanišnik Rižner
Journal:  Chem Biol Interact       Date:  2011-01-11       Impact factor: 5.192

4.  Structure-based inhibitor design for an enzyme that binds different steroids: a potent inhibitor for human type 5 17beta-hydroxysteroid dehydrogenase.

Authors:  Wei Qiu; Ming Zhou; Mausumi Mazumdar; Arezki Azzi; Dalila Ghanmi; Van Luu-The; Fernand Labrie; Sheng-Xiang Lin
Journal:  J Biol Chem       Date:  2006-12-13       Impact factor: 5.157

5.  Inhibition of a major NAD(P)-linked oxidoreductase from rat liver cytosol by steroidal and nonsteroidal anti-inflammatory agents and by prostaglandins.

Authors:  T M Penning; P Talalay
Journal:  Proc Natl Acad Sci U S A       Date:  1983-07       Impact factor: 11.205

6.  Development of nonsteroidal anti-inflammatory drug analogs and steroid carboxylates selective for human aldo-keto reductase isoforms: potential antineoplastic agents that work independently of cyclooxygenase isozymes.

Authors:  David R Bauman; Stephen I Rudnick; Lawrence M Szewczuk; Yi Jin; Sridhar Gopishetty; Trevor M Penning
Journal:  Mol Pharmacol       Date:  2004-10-08       Impact factor: 4.436

7.  The aldo-keto reductase AKR1C3 is a novel suppressor of cell differentiation that provides a plausible target for the non-cyclooxygenase-dependent antineoplastic actions of nonsteroidal anti-inflammatory drugs.

Authors:  Julian C Desmond; Joanne C Mountford; Mark T Drayson; Elizabeth A Walker; Martin Hewison; Jonathan P Ride; Quang T Luong; Rachel E Hayden; Elio F Vanin; Christopher M Bunce
Journal:  Cancer Res       Date:  2003-01-15       Impact factor: 12.701

8.  Crystal structures of prostaglandin D(2) 11-ketoreductase (AKR1C3) in complex with the nonsteroidal anti-inflammatory drugs flufenamic acid and indomethacin.

Authors:  Andrew L Lovering; Jon P Ride; Christopher M Bunce; Julian C Desmond; Stephen M Cummings; Scott A White
Journal:  Cancer Res       Date:  2004-03-01       Impact factor: 12.701

9.  Elevated AKR1C3 expression promotes prostate cancer cell survival and prostate cell-mediated endothelial cell tube formation: implications for prostate cancer progression.

Authors:  Mikhail G Dozmorov; Joseph T Azzarello; Jonathan D Wren; Kar-Ming Fung; Qing Yang; Jeffrey S Davis; Robert E Hurst; Daniel J Culkin; Trevor M Penning; Hsueh-Kung Lin
Journal:  BMC Cancer       Date:  2010-12-06       Impact factor: 4.430

10.  Expression of progesterone metabolizing enzyme genes (AKR1C1, AKR1C2, AKR1C3, SRD5A1, SRD5A2) is altered in human breast carcinoma.

Authors:  Michael J Lewis; John P Wiebe; J Godfrey Heathcote
Journal:  BMC Cancer       Date:  2004-06-22       Impact factor: 4.430

View more
  5 in total

Review 1.  AKR1C3 as a target in castrate resistant prostate cancer.

Authors:  Adegoke O Adeniji; Mo Chen; Trevor M Penning
Journal:  J Steroid Biochem Mol Biol       Date:  2013-06-06       Impact factor: 4.292

2.  Screening baccharin analogs as selective inhibitors against type 5 17β-hydroxysteroid dehydrogenase (AKR1C3).

Authors:  Tianzhu Zang; Kshitij Verma; Mo Chen; Yi Jin; Paul C Trippier; Trevor M Penning
Journal:  Chem Biol Interact       Date:  2014-12-31       Impact factor: 5.192

Review 3.  Aldo-Keto Reductase (AKR) 1C3 inhibitors: a patent review.

Authors:  Trevor M Penning
Journal:  Expert Opin Ther Pat       Date:  2017-09-19       Impact factor: 6.674

4.  Development of potent and selective indomethacin analogues for the inhibition of AKR1C3 (Type 5 17β-hydroxysteroid dehydrogenase/prostaglandin F synthase) in castrate-resistant prostate cancer.

Authors:  Andy J Liedtke; Adegoke O Adeniji; Mo Chen; Michael C Byrns; Yi Jin; David W Christianson; Lawrence J Marnett; Trevor M Penning
Journal:  J Med Chem       Date:  2013-03-13       Impact factor: 7.446

5.  Precursor-Directed Combinatorial Biosynthesis of Cinnamoyl, Dihydrocinnamoyl, and Benzoyl Anthranilates in Saccharomyces cerevisiae.

Authors:  Aymerick Eudes; Veronica Teixeira Benites; George Wang; Edward E K Baidoo; Taek Soon Lee; Jay D Keasling; Dominique Loqué
Journal:  PLoS One       Date:  2015-10-02       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.